Vertex Pharmaceuticals Incorporated

The most important fact in these filings is the swing from a 2024 loss to 2025 profit, paired with a business still concentrated in CF medicines. Operating income moved from negative $232.9 million in 2024 to $4.17 billion in 2025, and operating cash flow moved from negative $492.6 million to $3.63 billion. Operating cash flow was 0.92 times net income in 2025, meaning reported earnings were largely backed by cash. Total assets were $25.64 billion against $6.98 billion of liabilities, and equity rose to $18.67 billion from $16.41 billion. The forensic scores are explained here in plain English. The Beneish M-Score is -2.188, below the -1.78 threshold, so it is not in the elevated manipulation-risk zone; this is a screening result, not proof that the numbers are accurate or free of problems. The Altman Z-Score is 7.50, in the safe zone, which is a rough indicator of balance-sheet distress risk rather than a measure of value. The Piotroski F-Score is 6 of 7 computable signals, meaning six of the seven applicable fiscal-strength tests passed, with one not met. Readers may want to look at the Item 1A discussion of CASGEVY, where the filing says manufacturing cost as a percentage of revenue is significantly higher than for CF medicines and that side effects tied to the myeloablative preconditioning regimen could affect uptake, and at the JOURNAVX competition risk. The share repurchase program has used about $963 million of its $4.0 billion authorization since May 2025, a capital allocation choice that readers may want to compare against future operating cash flow. Overall, the data shows a profitable, cash-generating company whose results depend heavily on one franchise and on pricing policy outcomes outside its control.

Catalyst.Revenue for 2025 reached $12 billion, up 8.9% from $11.02 billion in 2024, and 2025 net income was $3.95 billion versus a $535.6 million loss in 2024. The 10-Q MD&A excerpt for the quarter ended March 31, 2026 is mostly forward-looking statement language, so it adds little quarterly financial detail. The drivers it names are continued growth of CF medicines through new approvals, label extensions, treatment of younger patients and expansion into additional geographies, plus the anticipated launch of povetacicept for IgAN, where the company refers to an expedited six-month FDA review after BLA acceptance. Management also reports repurchasing 741,135 shares in the first quarter of 2026 under a $4.0 billion program, with about $3.04 billion remaining.

Hidden risk.The filings show heavy concentration. The 10-K states that substantially all net product revenues come from CF medicines, and it says that concentration magnifies exposure to supply disruptions, safety issues and pricing pressure. Pricing risk is named specifically: the Colorado PDAB review that included TRIKAFTA, the Inflation Reduction Act, and a proposed CMS GUARD Model on most-favored-nation pricing, which the filing says could reduce pricing for the company's products. Ex-U.S. reimbursement has also been slow in some countries. The 2024 operating loss of $232.9 million and operating cash outflow of $492.6 million show how quickly results can swing, so the 2025 rebound of $4.17 billion in operating income is best read as one year within a longer series.